Earlier this month, healthcare artificial intelligence (AI) company Paige announced a new partnership with the renowned technology giant, Microsoft.
Paige describes itself as a company at the forefront of technology and healthcare, especially in the field of cancer diagnostics and pathology. The company explains its mission: “Led by a team of experts in the fields of life sciences, oncology, pathology, technology, machine learning, and healthcare strive] to transform cancer diagnostics.” We make it possible not only to provide additional information from digital slides to help pathologists perform their diagnostic work efficiently and confidently but also to go beyond by extracting novel insights from digital slides that can’t be seen by the naked eye. These unique tissue signatures have the potential to help guide treatment decisions and enable the development of novel biomarkers from tissues for diagnostic, pharmaceutical, and life sciences companies.
The company offers a variety of solutions. On the clinical front, Paige’s AI tools enable advanced diagnostics in the lab with computational pathology, which can be leveraged to identify complex tissue patterns. On the pharmaceutical front, the company’s tools offer new ways to identify and analyze tissue biomarkers, pushing forward diagnostic and predictive capabilities.
Given its new partnership with Microsoft, the goal will be to use the latter’s incredibly robust resources in healthcare and technology to further unlock value in Paige’s tools. Rightly so, Microsoft’s work in healthcare has grown tremendously in the last few years. The company has invested billions in developing important hardware tools such as HoloLens, which have genuine potential applications in the future of healthcare delivery. Moreover, the company has also invested significant time and resources on the software side. The company’s robust cloud offering in healthcare is the backbone of some of the largest healthcare organizations in the world.
